<DOC>
	<DOCNO>NCT02391168</DOCNO>
	<brief_summary>A multi-center , prospective cohort study natural history fatty liver disease China</brief_summary>
	<brief_title>Fatty Liver Disease Collaborative Research China</brief_title>
	<detailed_description>This multicenter , prospective open-enrollment epidemiologic study . All patient liver biopsy-proven macrovesicular steatosis ( &gt; 5 % ) enrol baseline cross-sectional analysis . Those either diagnosed NAFLD ALD , meet inclusion exclusion criterion , enrol follow cohort study , follow 1 year , 3 year 5 year visit window +1 month .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Fatty Liver , Alcoholic</mesh_term>
	<criteria>Clinically diagnose fatty liver disease , confirm liver biopsy . Specific biopsy requirement : qualify biopsy specimen within 6 month , &gt; 5 % hepatocytes show macrovesicular steatosis HE stain X10 microscope . Only patient NAFLD ALD eligible 5year followup cohort study . Willing participate longterm followup cooperative . Able provide inform consent file . Unable provide inform consent . Patients eligible baseline crosssectional analysis eligible cohort section , follow condition : 1 . Any endstage liver disease . 2 . Any malignant tumor . 3 . Any infection hepatitis virus HIV . 4 . Any congenital liver disease Wilson disease . 5 . Any serious disease project survival &lt; 5 year . 6 . Combined NAFLD ALD .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>